Literature DB >> 12842623

Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis.

Antero Airaksinen1, Nonia Pariente, Luis Menéndez-Arias, Esteban Domingo.   

Abstract

BHK-21 cells persistently infected with foot-and-mouth disease virus (FMDV) can be cured of virus by treatment with the antiviral nucleoside analogue ribavirin. To study whether the process involved an increase in the number of mutations in the mutant spectrum of the viral population, viral genomes were cloned from persistently infected cells treated or untreated with ribavirin. An increase of up to 10-fold in mutation frequencies associated with ribavirin treatment was observed in the viral genomes from the treated cultures as compared with parallel, untreated cultures. To address the possible mechanisms of enhanced mutagenesis, we investigated the mutagenic effects of ribavirin together with guanosine, and mycophenolic acid in the presence or absence of guanosine. Changes in the intracellular nucleotide concentrations were determined for all treatments. The results suggest that the increased mutation frequencies were not dependent on nucleotide pool imbalances or due to selection of preexisting genomes but they were produced by a mutagenic action of ribavirin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12842623     DOI: 10.1016/s0042-6822(03)00144-2

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  69 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

2.  Mutagenesis-induced, large fitness variations with an invariant arenavirus consensus genomic nucleotide sequence.

Authors:  Ana Grande-Pérez; Gema Gómez-Mariano; Pedro R Lowenstein; Esteban Domingo
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

3.  Hidden virulence determinants in a viral quasispecies in vivo.

Authors:  Marta Sanz-Ramos; Fayna Díaz-San Segundo; Cristina Escarmís; Esteban Domingo; Noemí Sevilla
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

4.  Ribavirin-resistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence.

Authors:  Jianxiong Zeng; Haiwei Wang; Xiaochun Xie; Chen Li; Guohui Zhou; Decheng Yang; Li Yu
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

5.  Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461.

Authors:  James I Mullins; Laura Heath; James P Hughes; Jessica Kicha; Sheila Styrchak; Kim G Wong; Ushnal Rao; Alexis Hansen; Kevin S Harris; Jean-Pierre Laurent; Deyu Li; Jeffrey H Simpson; John M Essigmann; Lawrence A Loeb; Jeffrey Parkins
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

6.  Evaluation of anti-HIV-1 mutagenic nucleoside analogues.

Authors:  Valérie Vivet-Boudou; Catherine Isel; Yazan El Safadi; Redmond P Smyth; Géraldine Laumond; Christiane Moog; Jean-Christophe Paillart; Roland Marquet
Journal:  J Biol Chem       Date:  2014-11-14       Impact factor: 5.157

Review 7.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Authors:  Diarmaid Hughes; Dan I Andersson
Journal:  Nat Rev Genet       Date:  2015-07-07       Impact factor: 53.242

8.  Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin.

Authors:  Armando Arias; Jamie J Arnold; Macarena Sierra; Eric D Smidansky; Esteban Domingo; Craig E Cameron
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

9.  Cell type mediated resistance of vesicular stomatitis virus and Sendai virus to ribavirin.

Authors:  Nirav R Shah; Amanda Sunderland; Valery Z Grdzelishvili
Journal:  PLoS One       Date:  2010-06-22       Impact factor: 3.240

10.  Potential benefits of sequential inhibitor-mutagen treatments of RNA virus infections.

Authors:  Celia Perales; Rubén Agudo; Hector Tejero; Susanna C Manrubia; Esteban Domingo
Journal:  PLoS Pathog       Date:  2009-11-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.